The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex

Biochemical Journal

Volumn 468, Issue 2, 2015, Pages 345-352

  Kolla, Venkatadri ^a   Naraparaju, Koumudi ^a   Zhuang, Tiangang ^a   Higashi, Mayumi ^a   Kolla, Sriharsha ^a   Blobel, Gerd A ^a   Brodeur, Garrett M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chromodomain helicase DNA binding protein 5 (CHD5); Neuroblastoma; Nuclear localization; Nucleosome remodelling histone deacetylase (NuRD) complex; Tumour suppressor

Indexed keywords

ANTIBODY; CALVASCULIN; CHROMODOMAIN HELICASE DNA BINDING PROTEIN 5; DNA BINDING PROTEIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; NUCLEOSOME REMODELLING HISTONE DEACETYLASE; POLYHISTIDINE TAG; RETINOBLASTOMA BINDING PROTEIN 4; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; URIDINE TRIACETATE; CADHERIN; LEUKOCYTE ANTIGEN; NUCLEOSOME; VASCULAR ENDOTHELIAL CADHERIN;

ARTICLE; CANCER INHIBITION; CHROMATIN; COMPLEX FORMATION; DNA BINDING MOTIF; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NUCLEOSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEQUENCE ANALYSIS; TESTIS; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; CELL NUCLEUS; CHROMATIN ASSEMBLY AND DISASSEMBLY; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; LIQUID CHROMATOGRAPHY; METABOLISM; NEUROBLASTOMA; PATHOLOGY; TANDEM MASS SPECTROMETRY; TUMOR CELL CULTURE;

EUKARYOTA;

ANTIGENS, CD; BLOTTING, WESTERN; CADHERINS; CELL NUCLEUS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATOGRAPHY, LIQUID; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MI-2 NUCLEOSOME REMODELING AND DEACETYLASE COMPLEX; NEUROBLASTOMA; NUCLEOSOMES; TANDEM MASS SPECTROMETRY; TUMOR CELLS, CULTURED;

EID: 84935024270     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20150030     Document Type: Article

References (56)

1. Brodeur, G. M. (2003) Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3, 203-216
2. Brodeur, G. M., Hogarty, M. D., Mosse, Y. P. and Maris, J. M. (2011) Neuroblastoma. In Principles and Practice of Pediatric Oncology (Pizzo, P. A. and Poplack, D. G., eds), pp. 886-922, Lippincott, Williams and Wilkins, Philadelphia
3. Mosse, Y. P., Greshock, J., Margolin, A., Naylor, T., Cole, K., Khazi, D., Hii, G., Winter, C., Shahzad, S., Asziz, M. U. et al. (2005) High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes Cancer 43, 390-403
4. Maris, J. M., White, P. S., Beltinger, C. P., Sulman, E. P., Castleberry, R. P., Shuster, J. J., Look, A. T. and Brodeur, G. M. (1995) Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res. 55, 4664-4669 PubMed
5. Attiyeh, E. F., London, W. B., Mosse, Y. P., Wang, Q., Winter, C., Khazi, D., McGrady, P. W., Seeger, R. C., Look, A. T., Shimada, H. et al. (2005) Chromosome 1p and 11q deletions and outcome in neuroblastoma. N. Engl. J. Med. 353, 2243-2253
6. Fong, C. T., Dracopoli, N. C., White, P. S., Merrill, P. T., Griffith, R. C., Housman, D. E. and Brodeur, G. M. (1989) Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc. Natl. Acad. Sci. U. S. A. 86, 3753-3757
7. Brodeur, G. M., Sekhon, G. and Goldstein, M. N. (1977) Chromosomal aberrations in human neuroblastomas. Cancer 40, 2256-2263
8. White, P. S., Maris, J. M., Beltinger, C., Sulman, E., Marshall, H. N., Fujimori, M., Kaufman, B. A., Biegel, J. A., Allen, C., Hilliard, C. et al. (1995) A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc. Natl. Acad. Sci. U. S. A. 92, 5520-5524
9. Fujita, T., Igarashi, J., Okawa, E. R., Gotoh, T., Manne, J., Kolla, V., Kim, J., Zhao, H., Pawel, B. R., London, W. B. et al. (2008) CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J. Natl. Cancer Inst. 100, 940-949
10. Okawa, E. R., Gotoh, T., Manne, J., Igarashi, J., Fujita, T., Silverman, K. A., Xhao, H., Mosse, Y. P., White, P. S. and Brodeur, G. M. (2008) Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene 27, 803-810
11. Thompson, P. M., Gotoh, T., Kok, M., White, P. S. and Brodeur, G. M. (2003) CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 22, 1002-1011
12. White, P. S., Thompson, P. M., Gotoh, T., Okawa, E. R., Igarashi, J., Kok, M., Winter, C., Gregory, S. G., Hogarty, M. D., Maris, J. M. and Brodeur, G. M. (2005) Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 24, 2684-2694
13. Garcia, I., Mayol, G., Rodriguez, E., Sunol, M., Gershon, T. R., Rios, J., Cheung, N. K., Kieran, M. W., George, R. E., Perez-Atayde, A. R. et al. (2010) Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol. Cancer 9, 277
14. Koyama, H., Zhuang, T., Light, J. E., Kolla, V., Higashi, M., McGrady, P. W., London, W. B. and Brodeur, G. M. (2012) Mechanisms of CHD5 Inactivation in neuroblastomas. Clin. Cancer Res. 18, 1588-1597
15. Bagchi, A., Papazoglu, C., Wu, Y., Capurso, D., Brodt, M., Francis, D., Bredel, M., Vogel, H. and Mills, A. A. (2007) CHD5 is a tumor suppressor at human 1p36. Cell 128, 459-475
16. Law, M. E., Templeton, K. L., Kitange, G., Smith, J., Misra, A., Feuerstein, B. G. and Jenkins, R. B. (2005) Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines. Cancer Genet. Cytogenet. 160, 1-14
17. Lang, J., Tobias, E. S. and Mackie, R. (2011) Preliminary evidence for involvement of the tumour suppressor gene CHD5 in a family with cutaneous melanoma. Br. J. Dermatol. 164, 1010-1016
18. Ng, D., Yang, X. R., Tucker, M. A. and Goldstein, A. M. (2008) Mutation screening of CHD5 in melanoma-prone families linked to 1p36 revealed no deleterious coding or splice site changes. BMC Res. Notes 1, 86
19. Wu, X., Zhu, Z., Li, W., Fu, X., Su, D., Fu, L., Zhang, Z., Luo, A., Sun, X., Fu, L. and Dong, J. T. (2012) Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer. Breast Cancer Res. 14, R73
20. Mokarram, P., Kumar, K., Brim, H., Naghibalhossaini, F., Saberi-firoozi, M., Nouraie, M., Green, R., Lee, E., Smoot, D. T. and Ashktorab, H. (2009) Distinct high-profile methylated genes in colorectal cancer. PLoS One 4, e7012
21. Cai, C., Ashktorab, H., Pang, X., Zhao, Y., Sha, W., Liu, Y. and Gu, X. (2012) MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. PLoS One 7, e29750
22. Wang, X., Lau, K. K., So, L. K. and Lam, Y. W. (2009) CHD5 is down-regulated through promoter hypermethylation in gastric cancer. J. Biomed. Sci. 16, 95
23. Zhao, R., Yan, Q., Lv, J., Huang, H., Zheng, W., Zhang, B. and Ma, W. (2012) CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. Lung Cancer 76, 324-331
24. Gorringe, K. L., Choong, D. Y., Williams, L. H., Ramakrishna, M., Sridhar, A., Qiu, W., Bearfoot, J. L. and Campbell, I. G. (2008) Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia 10, 1253-1258 PubMed
25. Wong, R. R., Chan, L. K., Tsang, T. P., Lee, C. W., Cheung, T. H., Yim, S. F., Siu, N. S., Lee, S. N., Yu, M. Y., Chim, S. S. et al. (2011) chd5 downregulation associated with poor prognosis in epithelial ovarian cancer. Gynecol. Obstet. Invest. 72, 203-207
26. Robbins, C. M., Tembe, W. A., Baker, A., Sinari, S., Moses, T. Y., Beckstrom-Sternberg, S., Beckstrom-Sternberg, J., Barrett, M., Long, J., Chinnaiyan, A. et al. (2011) Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res. 21, 47-55
27. Kolla, V., Zhuang, T., Higashi, M., Naraparaju, K. and Brodeur, G. M. (2014) Role of CHD5 in human cancers: 10 years later. Cancer Res. 74, 652-658
28. Lai, A. Y. and Wade, P. A. (2011) Cancer biology and NuRD: a multifaceted chromatin remodelling complex. Nat. Rev. Cancer 11, 588-596
29. Marfella, C. G. and Imbalzano, A. N. (2007) The Chd family of chromatin remodelers. Mutat. Res. 618, 30-40
30. Hall, J. A. and Georgel, P. T. (2007) CHD proteins: a diverse family with strong ties. Biochem. Cell Biol. 85, 463-476
31. Ramirez, J., Dege, C., Kutateladze, T. G. and Hagman, J. (2012) MBD2 and multiple domains of CHD4 are required for transcriptional repression by Mi-2/NuRD complexes. Mol. Cell Biol. 32, 5078-5088
32. Woodage, T., Basrai, M. A., Baxevanis, A. D., Hieter, P. and Collins, F. S. (1997) Characterization of the CHD family of proteins. Proc. Natl. Acad. Sci. U. S. A. 94, 11472-11477
33. Zhuang, T., Hess, R. A., Kolla, V., Higashi, M., Raabe, T. D. and Brodeur, G. M. (2014) CHD5 is required for spermiogenesis and chromatin condensation. Mech. Dev. 131, 35-46
34. Tong, J. K., Hassig, C. A., Schnitzler, G. R., Kingston, R. E. and Schreiber, S. L. (1998) Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. Nature 395, 917-921
35. Xue, Y., Wong, J., Moreno, G. T., Young, M. K., Cote, J. and Wang, W. (1998) NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol. Cell. 2, 851-861
36. Hargreaves, D. C. and Crabtree, G. R. (2011) ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res. 21, 396-420
37. Denslow, S. A. and Wade, P. A. (2007) The human Mi-2/NuRD complex and gene regulation. Oncogene 26, 5433-5438
38. Allen, H. F., Wade, P. A. and Kutateladze, T. G. (2013) The NuRD architecture. Cell. Mol. Life Sci. 70, 3513-3524
39. Wang, L., He, S., Tu, Y., Ji, P., Zong, J., Zhang, J., Feng, F., Zhao, J., Gao, G. and Zhang, Y. (2013) Downregulation of chromatin remodeling factor CHD5 is associated with a poor prognosis in human glioma. J. Clin. Neurosci. 20, 958-963
40. Stanley, F. K., Moore, S. and Goodarzi, A. A. (2013) CHD chromatin remodelling enzymes and the DNA damage response. Mutat. Res. 750, 31-44
41. Li, D. Q. and Kumar, R. (2010) Mi-2/NuRD complex making inroads into DNA-damage response pathway. Cell Cycle 9, 2071-2079
42. Egan, C. M., Nyman, U., Skotte, J., Streubel, G., Turner, S., O'Connell, D. J., Rraklli, V., Dolan, M. J., Chadderton, N., Hansen, K. et al. (2013) CHD5 is required for neurogenesis and has a dual role in facilitating gene expression and polycomb gene repression. Dev. Cell 26, 223-236
43. Potts, R. C., Zhang, P., Wurster, A. L., Precht, P., Mughal, M. R., Wood, III, W. H., Zhang, Y., Becker, K. G., Mattson, M. P. and Pazin, M. J. (2011) CHD5, a brain-specific paralog of Mi2 chromatin remodeling enzymes, regulates expression of neuronal genes. PLoS One 6, e24515
44. Hong, W., Nakazawa, M., Chen, Y. Y., Kori, R., Vakoc, C. R., Rakowski, C. and Blobel, G. A. (2005) FOG-1 recruits the NuRD repressor complex to mediate transcriptional repression by GATA-1. EMBO J. 24, 2367-2378
45. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685
46. Shevchenko, A., Wilm, M., Vorm, O. and Mann, M. (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68, 850-858
47. Peng, J. and Gygi, S. P. (2001) Proteomics: the move to mixtures. J. Mass Spectrom. 36, 1083-1091
48. Eng, J. K., McCormack, A. L. and Yates, J. R. (1994) An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J. Am. Soc. Mass Spectrom. 5, 976-989
49. Miccio, A., Wang, Y., Hong, W., Gregory, G. D., Wang, H., Yu, X., Choi, J. K., Shelat, S., Tong, W., Poncz, M. and Blobel, G. A. (2010) NuRD mediates activating and repressive functions of GATA-1 and FOG-1 during blood development. EMBO J. 29, 442-456
50. Vestin, A. and Mills, A. A. (2013) The tumor suppressor Chd5 is induced during neuronal differentiation in the developing mouse brain. Gene Expr. Patterns 13, 482-489
51. Li, W., Wu, J., Kim, S. Y., Zhao, M., Hearn, S. A., Zhang, M. Q., Meistrich, M. L. and Mills, A. A. (2014) Chd5 orchestrates chromatin remodelling during sperm development. Nat. Commun. 5, 3812 PubMed
52. Steilmann, C., Cavalcanti, M. C., Bergmann, M., Kliesch, S., Weidner, W. and Steger, K. (2010) Aberrant mRNA expression of chromatin remodelling factors in round spermatid maturation arrest compared with normal human spermatogenesis. Mol. Hum. Reprod. 16, 726-733
53. Paul, S., Kuo, A., Schalch, T., Vogel, H., Joshua-Tor, L., McCombie, W. R., Gozani, O., Hammell, M. and Mills, A. A. (2013) Chd5 requires PHD-mediated histone 3 binding for tumor suppression. Cell Rep. 3, 92-102
54. Mulero-Navarro, S. and Esteller, M. (2008) Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. Epigenetics 3, 210-215
55. Qu, Y., Dang, S. and Hou, P. (2013) Gene methylation in gastric cancer. Clin. Chim. Acta 424, 53-65
56. Wang, J., Chen, H., Fu, S., Xu, Z. M., Sun, K. L. and Fu, W. N. (2011) The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma. Oral. Oncol. 47, 601-608